PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...

New data show excellent quality-of-life outcomes and effective tumor control for both intensity-modulated radiation therapy ...

Şeyma will report directly to the President of International Markets and will be based in Istanbul. As a member of the ...

Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. | ...

Astellas is rolling out its first DTC campaign to raise awareness about an injection that treats geographic atrophy.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

The Federal Circuit has vacated a District of Delaware ruling in a patent case which found that patent claims asserted by ...

North America Cancer Immunotherapy Market is expanding rapidly due to expanding approval of immunotherapeutic drugs for the treatment of increasing incidences of cancer and increasing investments in ...

Zydus Lifesciences has received a significant approval from the US FDA for Enzalutamide capsules, which are used in treatment ...

Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorders.